Dwi Nanda Satriyo Arif Wibowo

Dwi Nanda Satriyo Arif Wibowo

Auto-generated profile, based on publicly available information

Dwi Nanda Satriyo Arif Wibowo

Department of Urology, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General- Academic Hospital, Surabaya, Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Urology Research and Practice
Verified
Journal Article
Closed access
DWDwi Nanda Satriyo Arif Wibowo
Dwi Nanda Satriyo Arif Wibowo
DSDoddy Moesbadianto Soebadi
Doddy Moesbadianto Soebadi
YSYodi Soebadi
Yodi Soebadi
In recent years, several studies have reported promising results of Yohimbine as a natural supplement for erectile dysfunction (ED). However, several studies suggested that the aphrodisiac effects of the extract were only a placebo or due to the increase in peripheral vascular congestion. In contrast, other studies reported that it could provide excellent curative effects on organic impotence. We aimed to review the efficacy of Yohimbine as a pharmacological treatment for ED and performed a comprehensive systematic search of published articles in PubMed and Science Direct databases for eligible randomized controlled trials comparing Yohimbine to placebo or no treatment for ED patients. A total of eight studies out of 543 studies were included in this review. Both Yohimbine alone (odds ratio [OR] ¼ 2.08, 95% CI 1.30-3.32, P ¼ .002) and combined (OR ¼ 6.35, 95% CI 3.01-13.41, P < .001) showed a significantly greater probability of erectile function improvement compared to the placebo group (OR ¼ 2.87, 95% CI 1.94-4.25, P < .001). Yohimbine alone did not show a significant difference in the rate of improved sexual function (P ¼ .07); however, the pooled results of both subgroups indicated a higher rate of improved sexual function (OR ¼ 2.65, 95% CI 1.43-4.92, P ¼ .002). Sole administration of Yohimbine and its combination with other supplements can improve the erectile function in ED patients. However, it is not able to improve the sexual function if not combined with other treatments. Cite this article as: Wibowo DNSA, Soebadi DM, Soebadi MA. Yohimbine as a treatment for erectile dysfunction: A systematic review and meta-analysis. Turk J Urol. 2021;47(6):482-488

27 June 2021 in Journal of Clinical Urology
Verified
Journal Article
Closed access
PDF file
DWDnsa Wibowo
Dnsa Wibowo
DSDoddy M Soebadi
Doddy M Soebadi
FRFikri Rizaldi
Fikri Rizaldi
Objectives: The aim of this study was to evaluate the impact of body mass index (BMI) on percutaneous nephrolithotomy (PCNL) outcomes and complications for nephrolithiasis. Patients and methods: Patients with a history of PCNL surgery from 2012 to 2017 in Dr. Soetomo General-Academic Hospital were retrospectively evaluated. Patients were then categorized into four groups: underweight (BMI <18.5 kg/m2), normal (BMI 18.5 to 24.99 kg/m2), overweight (BMI ⩾25–29.9 kg/m2), and obese (BMI ⩾30 kg/m2). The association between BMI, subjects’ characteristics, length of stay, stone-free rate (SFR), and complications were analyzed using one-way analysis of variance (ANOVA) and univariate logistic regression. Results: The study included 430 male patients (58%) and 310 female patients (42%). They were classified based on their BMI into underweight ( n = 5, 1%), normal weight ( n = 291, 39%), overweight ( n = 271, 37%), and obese ( n = 173, 23%) groups. The underweight BMI group had a higher average blood loss ( p=0.002) compared to the other groups; however, the univariate logistic regression showed that BMI had no significant effect on SFR ( p=0.491). Conclusion: PCNL is safe and feasible to be performed in patients with different BMI as obesity has no impact on the outcomes and complications associated with PCNL. Level of evidence: 3